Disc Medicine Q2 Loss Widens to $1.54/Share; $718M Cash Funds Operations into 2029
IRON sits 85% above its 52-week low of $40.
Summary
Disc Medicine's Q2 loss of $1.54/share missed estimates, but $717.7M in cash provides runway into 2029. The company also amended executive employment agreements and disclosed new insider trading plans.
Key Events · Earnings and Guidance · IRON
-
Q2 Loss Misses Estimates
Net loss of $59.5M ($1.54/share) vs. consensus ~$1.20, driven by higher R&D and SG&A spending as pipeline advances.
-
Cash Runway Extended into 2029
$717.7M in cash and marketable securities as of June 30, 2026, expected to fund operations into 2029 without relying on product revenue.
-
Executive Employment Agreements Amended
Amended and restated employment agreements for CEO, CFO, CCO, CMO, and COO with enhanced severance terms, including accelerated equity vesting upon a change in control.
-
Insider Trading Plans Adopted
Chief Medical Officer and Chief Financial Officer adopted 10b5-1 trading plans to sell up to 32,070 and 22,917 shares, respectively, through end-2026/2027.
Analysis · IRON · Life Sciences
Disc Medicine reported a Q2 net loss of $59.5 million, or $1.54 per share, missing consensus estimates by roughly 28%. The miss was driven by higher R&D and SG&A expenses as the company advances its pipeline. Despite the wider loss, the company holds $717.7 million in cash and marketable securities, which management expects will fund operations into 2029 — a critical survival signal for a pre-revenue biotech. The filing also disclosed amended employment agreements for five top executives with enhanced change-in-control severance, and the adoption of 10b5-1 trading plans by the Chief Medical Officer and CFO, signaling planned insider sales. Additionally, the company drew an extra $30 million under its Hercules loan facility, bringing total debt to $60 million. The cash position and extended runway are the key takeaways, offsetting the earnings miss and providing a buffer as the company awaits pivotal Phase 3 data for bitopertin in Q4 2026.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 38.6% of the 924 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IRON was trading at $73.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $40.00 to $99.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.